PBA
MANE

Paradigm Biocapital Advisors’s Veradermics Inc MANE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio MANE Stock Details MANE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-525,000
Closed -$33.2M – 42
2026
Q1 		$33.2M Buy
+525,000
New +$26.5M 0.68% 27

Other funds holding MANE

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Paradigm Biocapital Advisors's MANE Position: Q2 2026 in Review

Paradigm Biocapital Advisors sold out of Veradermics Inc (MANE) in Q2 2026, closing a stake of 525,000 shares — an estimated $33.2M sold.

Paradigm Biocapital Advisors first reported a position in MANE in Q1 2026 and held it in 1 quarter. The position peaked at $33.2M in Q1 2026. 164 funds tracked by Wall St. Rank hold MANE as of Q2 2026.

  • Paradigm Biocapital Advisors reported no remaining Veradermics Inc position as of Q2 2026 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 525,000 Veradermics Inc shares in Q2 2026, an estimated $33.2M.
  • Paradigm Biocapital Advisors first reported a position in Veradermics Inc in Q1 2026 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's Veradermics Inc position peaked at $33.2M in Q1 2026.
  • 164 funds tracked by Wall St. Rank held Veradermics Inc as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.